The treatment is not a quick fix, but rather a part of a long-term strategy to support healthier habits and improved well-being
Bramante, thanks for joining us here on Minnesota Now
The starting dose is designed for tolerance building, not maximum effect
The limitations include the relatively small sample size of the MASLD substudy, the geographic and racial homogeneity of the sample (United States only and majority white), the exclusion of patients with T2D, the absence of liver histology, the lack of enrichment for MASH or significant fibrosis, the lack of multiplicity control given the large number of statistical assessments and the absence of 48-week MRI data for 56.1% of participants, which limits interpretation of the dose-response relationship for liver fat reduction at 48 weeks
Eligibility: Specific BMI requirements, age ranges, and health criteria
Conclusion Transparent details guide consumers to balance the reality about retatrutide and its role in treatment